Safety of 4-Nitrobenzoic acid. In 2020.0 ACS MED CHEM LETT published article about HISTONE DEACETYLASE INHIBITOR; ACCURATE DOCKING; IN-VITRO; GLIDE; RICOLINOSTAT; MODEL; CELL in [Shouksmith, Andrew E.; Gawel, Justyna M.; Nawar, Nabanita; Sina, Diana; Raouf, Yasir S.; Bukhari, Shazreh; He, Liying; Johns, Alexandra E.; Manaswiyoungkul, Pimyupa; Olaoye, Olasunkanmi O.; Cabral, Aaron D.; Sedighi, Abootaleb; de Araujo, Elvin D.; Gunning, Patrick T.] Univ Toronto Mississauga, Dept Chem & Phys Sci, 3359 Mississauga Rd, Mississauga, ON L5L 1C6, Canada in 2020.0, Cited 25.0. The Name is 4-Nitrobenzoic acid. Through research, I have a further understanding and discovery of 62-23-7.
The HDAC inhibitor 4-tert-butyl-N-(4-(hydroxycarbamoyl)phenyl)benzamide (AES-350, 51) was identified as a promising preclinical candidate for the treatment of acute myeloid leukemia (AML), an aggressive malignancy with a meagre 24% 5-year survival rate. Through screening of low-molecular-weight analogues derived from the previously discovered novel HDAC inhibitor, AES-135, compound 51 demonstrated greater HDAC isoform selectivity, higher cytotoxicity in MV4-11 cells, an improved therapeutic window, and more efficient absorption through cellular and lipid membranes. Compound 51 also demonstrated improved oral bioavailability compared to SAHA in mouse models. A broad spectrum of experiments, including FACS, ELISA, and Western blotting, were performed to support our hypothesis that 51 dose-dependently triggers apoptosis in AML cells through HDAC inhibition.
Safety of 4-Nitrobenzoic acid. About 4-Nitrobenzoic acid, If you have any questions, you can contact Shouksmith, AE; Gawel, JM; Nawar, N; Sina, D; Raouf, YS; Bukhari, S; He, LY; Johns, AE; Manaswiyoungkul, P; Olaoye, OO; Cabral, AD; Sedighi, A; de Araujo, ED; Gunning, PT or concate me.
Reference:
Phthalazine – Wikipedia,
,Phthalazine | C8H6N2 – PubChem